AEON earnings analysis
What we found in AEON's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
AEON’s Q2 diluted loss improved to $0.02 per share from $0.60 year over year and $0.29 in Q1 2026, but the filing does not provide revenue, margin, segment, or free-cash-flow data. Approximately $13.6 million of July financing proceeds extends the expected operating runway into Q1 2027, while the $15.361 million stockholders’ deficit and continuing losses remain significant concerns. The newly issued pre-funded and milestone warrants add material dilution risk, although the Aegis lawsuit was dismissed with prejudice in April 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Quarterly loss narrowed materially
- Second-quarter diluted loss narrowed to $0.02 per share from a $0.60 loss in the prior-year quarter and a $0.29 loss in Q1 2026.
- Financing extends operating runway
- The July 2026 financing generated approximately $13.6 million of net proceeds, with liquidity expected to fund operations into Q1 2027.
- Disclosure controls remained effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
- Capital-markets lawsuit dismissed
- AEON’s motion to dismiss Aegis Capital’s lawsuit was granted with prejudice in April 2026; Aegis had claimed $1.59 million in damages and did not appeal.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- New financing creates dilution risk
- The July 2026 financing included common shares, pre-funded warrants, and two-year and five-year milestone warrants. Exercise of these instruments could materially dilute existing holders and create trading pressure.
- Limited liquidity runway
- The company has approximately $13.6 million of July financing proceeds expected to fund operations only into Q1 2027, indicating that additional capital may be needed thereafter.
- Deficit and continuing-loss risk
- AEON reported a $15.361 million stockholders’ deficit and continues to incur operating losses, increasing dependence on future financing and successful product development.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.02
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management indicated that approximately $13.6 million of July 2026 financing proceeds are expected to fund operations into Q1 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- AEON Biopharma reported no revenue in its Q4 2026 quarterly filing, with a notable EPS decline to -3.72 from -0.6 in the previous quarter. Operating expenses increased primarily due to rising SG&A and R&D costs. The…
- 10-K · March 30, 2026
- AEON’s 10-K frames a focused strategy to commercialize ABP-450 as a Section 351(k) biosimilar to Botox® for therapeutic indications, highlighting strong early analytical comparability data (100% amino acid identity;…
- 10-Q · November 14, 2025
- AEON reported a narrower net loss in Q3 2025 of $4.538 million (basic EPS -$0.39) versus a loss of $6.171 million (EPS -$11.24) in Q3 2024, driven by lower operating expenses and non‑cash fair value movements. Cash…
- 10-Q · May 14, 2025
- AEON reported a non-cash net income of $9,095,000 for Q1 2025 (vs. a net loss of $118,018,000 in Q1 2024) driven by fair‑value movements in warrants and related instruments. Operating loss narrowed to $(462,000) from…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AEON makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever